98%
921
2 minutes
20
Reversible and irreversible amyloids are two diverging cases of protein (mis)folding associated with the cross-β motif in the protein folding and aggregation energy landscape. Yet, the molecular origins responsible for the formation of reversible vs irreversible amyloids have remained unknown. Here we provide evidence at the atomic level of distinct folding motifs for irreversible and reversible amyloids derived from a single protein sequence: human lysozyme. We compare the 2.8 Å structure of irreversible amyloid fibrils determined by cryo-electron microscopy helical reconstructions with molecular insights gained by solid-state NMR spectroscopy on reversible amyloids. We observe a canonical cross-β-sheet structure in irreversible amyloids, whereas in reversible amyloids, there is a less-ordered coexistence of β-sheet and helical secondary structures that originate from a partially unfolded lysozyme, thus carrying a "memory" of the original folded protein precursor. We also report the structure of hen egg-white lysozyme irreversible amyloids at 3.2 Å resolution, revealing another canonical amyloid fold, and reaffirming that irreversible amyloids undergo a complete conversion of the native protein into the cross-β structure. By combining atomic force microscopy, cryo-electron microscopy and solid-state NMR, we show that a full unfolding of the native protein precursor is a requirement for establishing irreversible amyloid fibrils.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442456 | PMC |
http://dx.doi.org/10.1038/s41467-024-52681-z | DOI Listing |
Tissue Barriers
September 2025
Department of Biomedical Engineering, Univ of South Carolina, Columbia, SC, USA.
Blood-brain barrier (BBB) dysfunction is an early event observed in Alzheimer's disease (AD). Two characteristics of AD brain and brain vasculature contribute to BBB dysfunction: the accumulation of aggregated amyloid-β protein (Aβ) and an increase in oxidative stress. This work uses a BBB model of primary human brain microvascular endothelial cells to investigate the individual and synergistic influence of both pathogenic Aβ oligomers and oxidative stress on BBB transendothelial electrical resistance (TEER), an indicator of barrier integrity.
View Article and Find Full Text PDFExp Ther Med
October 2025
Department of Hematology, Luohu People's Hospital of Shenzhen, Shenzhen, Guangdong 518005, P.R. China.
Cardiac light chain amyloidosis (AL) secondary to Waldenström's macroglobulinemia (WM) presents a complex challenge in medical practice due to its rarity and diagnostic difficulty. A 67-year-old male presented with symptoms of heart failure and was diagnosed with cardiac AL amyloidosis secondary to WM. The diagnosis of WM was confirmed through a combination of immunoglobulin (Ig) profile with abnormal IgM levels, bone marrow morphology, immunofixation electrophoresis, serum protein electrophoresis and gene mutation analysis.
View Article and Find Full Text PDFBrain Behav Immun
August 2025
Shaanxi Key Laboratory of Brain Disorders & Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, PR China.
Alzheimer's disease (AD), a progressive neurodegenerative disorder characterized by irreversible cognitive decline and cerebral dysfunction, remains a major global health challenge due to elusive pathogenesis and the lack of disease-modifying therapies. Growing evidence underscores the neuroprotective potential of ketone bodies, particularly β-hydroxybutyrate (β-HB), owing to their diverse biological roles in mitigating AD-related pathology. Recent advances also implicate innate immunity in AD progression, identifying interferon-induced transmembrane protein 3 (IFITM3) as a pivotal regulator of amyloid-β (Aβ) formation.
View Article and Find Full Text PDFInt J Mol Sci
August 2025
Clinic of Psychiatry, Department of Psychiatry, Wroclaw Medical University, Ludwika Pasteura 10, 50-367 Wrocław, Poland.
Alzheimer's disease (AD) is an irreversible neurodegenerative disease of the central nervous system, responsible for 60-80% of dementia. Its pathogenesis is mainly based on the accumulation of beta-amyloid and tau proteins. Current pharmacological treatment includes acetylcholinesterase inhibitors, NMDA receptor antagonists, and monoclonal antibodies.
View Article and Find Full Text PDFFront Immunol
August 2025
Boston University Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, United States.
Introduction: Systemic AL amyloidosis is caused by deposition of monoclonal antibody light chains (LC) as insoluble amyloid fibrils in multiple tissues, leading to irreversible and eventually fatal organ damage. Each patient has a unique LC sequence that appears to define its propensity to aggregate. The complexity and diversity of LC sequences has impeded efforts to understand why some LCs aggregate to cause disease while others do not.
View Article and Find Full Text PDF